A subset of HIV-infected individuals who receive antiretroviral therapy (ART) develop a paradoxical pathological response that significantly increases morbidity and sometimes mortality. Following the induction of highly active ART, a rapid decline in the viral load results within weeks and coincides with a steep rise in the CD4+ T-cell counts and immune hyperactivation. Although no mechanistic pathway has been elucidated for the development of immune reconstitution inflammatory syndrome (IRIS), it is thought that change in the nature of the immune response is a predominant factor in the development of reconstitution disease. In this article, we review the current state of knowledge in this field and provide a model for the development of IRIS.
MocroftA, VellaS, BenfieldTL.Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.Lancet1998; 352: 1725–30
2.
RobertsonJ, MeierM, WallJ, YingJ, FichtenbaumCJ.Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.Clin Infect Dis2006; 42: 1639–46
3.
TorreD, SperanzaF, MarteganiR.Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.HIV Med2005; 6: 66–78
CarrA, CooperDA.Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor.Lancet1997; 349: 995–6
6.
RaceEM, Adelson-MittyJ, KriegelGR.Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.Lancet1998; 351: 252–5
7.
FrenchMA, LenzoN, JohnM.Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.HIV Med2000; 1: 107–15
ShelburneSA, VisnegarwalaF, DarcourtJ.Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.AIDS2005; 19: 399–406
10.
RatnamI, ChiuC, KandalaNB, EasterbrookPJ.Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.Clin Infect Dis2006; 42: 418–27
HuruyK, MuluA, MengistuG.Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia.Jpn J Infect Dis2008; 61: 205–9
13.
FrenchM, KeaneN, McKinnonE, PhungS, PriceP.Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.HIV Med2007; 8: 148–55
14.
BadriM, WilsonD, WoodR.Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.Lancet2002; 359: 2059–64
15.
KrupicaTJr, FryTJ, MackallCL.Autoimmunity during lymphopenia: a two-hit model.Clin Immunol2006; 120: 121–8
16.
BonyhadiML, RabinL, SalimiS.HIV induces thymus depletion in vivo.Nature1993; 363: 728–32
17.
ZhangL, LewinSR, MarkowitzM.Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.J Exp Med1999; 190: 725–32
18.
CarcelainG, DebreP, AutranB.Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy.Curr Opin Immunol2001; 13: 483–8
19.
SaagMS.The impact of highly active antiretroviral therapy on HIV-specific immune function.AIDS2001; 15 (Suppl 2): S4–10
20.
AutranB, CarcelainG, LiTS.Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.Science1997; 277: 112–6
21.
LedermanMM.Immune restoration and CD4+ T-cell function with antiretroviral therapies.AIDS2001; 15 (Suppl 2): S11–5
22.
BucyRP, HockettRD, DerdeynCA.Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.J Clin Invest1999; 103: 1391–8
MarchettiG, FranzettiF, GoriA.Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?J Antimicrob Chemother2005; 55: 401–9
25.
SriramU, WongM, CaillierSJ.Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy.AIDS Res Hum Retroviruses2007; 23: 741–7
26.
AutranB, CarcelaintG, LiTS.Restoration of the immune system with anti-retroviral therapy.Immunol Lett1999; 66: 207–11
27.
ZaphC, UzonnaJ, BeverleySM, ScottP.Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites.Nat Med2004; 10: 1104–10
28.
AnderssonJ, FehnigerTE, PattersonBK.Early reduction of immune activation in lymphoid tissue following highly active HIV therapy.AIDS1998; 12: F123–9
29.
SmithKY, ValdezH, LandayA.Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.J Infect Dis2000; 181: 141–7
30.
SmithKA.Interleukin-2: inception, impact, and implications.Science1988; 240: 1169–76
31.
DurierC, CapitantC, LascauxAS.Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).AIDS2007; 21: 1887–97
NapolitanoLA, GrantRM, DeeksSG.Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis.Nat Med2001; 7: 73–9
34.
FluurC, De MilitoA, FryTJ.Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection.J Immunol2007; 178: 5340–50
35.
PacanowskiJ, KahiS, BailletM.Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection.Blood2001; 98: 3016–21
36.
CarbonneilC, Donkova-PetriniV, AoubaA, WeissL.Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4 + CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-alpha.J Immunol2004; 172: 7832–40
37.
FeldmanS, SteinD, AmruteS.Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors.Clin Immunol2001; 101: 201–10
38.
KunduSK, EnglemanE, BenikeC.A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.AIDS Res Hum Retroviruses1998; 14: 551–60
39.
SindhuS, TomaE, CordeiroP, AhmadR, MorissetR, MenezesJ.Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.J Med Virol2006; 78: 431–9
40.
DeSimoneJA, PomerantzRJ, BabinchakTJ.Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.Ann Intern Med2000; 133: 447–54
41.
SutherlandR, YangH, ScribaTJ.Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART.AIDS2006; 20: 821–9
42.
LamanJD, ClaassenE, Van RooijenN, BoersmaWJ.Immune complexes on follicular dendritic cells as atarget for cytolytic cells in AIDS.AIDS1989; 3: 543–4
43.
AppayV, NixonDF, DonahoeSM.HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.J Exp Med2000; 192: 63–75
44.
Gea-BanaclocheJC, MiguelesSA, MartinoL.Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors.J Immunol2000; 165: 1082–92
45.
JanssenEM, DroinNM, LemmensEE.CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.Nature2005; 434: 88–93
46.
PitcherCJ, QuittnerC, PetersonDM.HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.Nat Med1999; 5: 518–25
47.
SakaguchiS, PowrieF.Emerging challenges in regulatory T cell function and biology.Science2007; 317: 627–9
48.
AlmeidaAR, ZaragozaB, FreitasAA.Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4 + CD25+ regulatory T cells is indexed to the number of IL-2-producing cells.J Immunol2006; 177: 192–200
49.
Oswald-RichterK, GrillSM, ShariatN.HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells.PLoS Biol2004; 2: E198
50.
MontesM, LewisDE, SanchezC.Foxp3+ regulatory T cells in antiretroviral-naive HIV patients.AIDS2006; 20: 1669–71
51.
LimA, TanD, PriceP.Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.AIDS2007; 21: 1525–34
52.
JesserRD, LiS, WeinbergA.Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation.Virology2006; 352: 408–17
53.
MozosA, GarridoM, CarrerasJ.Redistribution of FOXP3-positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-infected patients.J Acquir Immune Defic Syndr2007; 46: 529–37
54.
PriceP, MathiotN, KruegerR, StoneS, KeaneNM, FrenchMA.Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy.J Clin Virol2001; 22: 279–87
55.
WeissL, Donkova-PetriniV, CaccavelliL, BalboM, CarbonneilC, LevyY.Human immunodeficiency virus-driven expansion of CD4 + CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients.Blood2004; 104: 3249–56
56.
NishiokaT, NishidaE, IidaR, MoritaA, ShimizuJ.In vivo expansion of CD4(+)Foxp3(+) regulatory T cells mediated by GITR molecules.Immunol Lett2008; 121: 97–104
57.
MoriS, KocakU, ShawJL, MullenCA.Augmentation of post transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T-cell responses in the post transplant repertoire.Bone Marrow Transplant2005; 35: 793–801
58.
ChenX, Vodanovic-JankovicS, JohnsonB, KellerM, KomorowskiR, DrobyskiWR.Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.Blood2007; 110: 3804–13
